GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

NCT02082496 on ClinicalTrials.gov · last registry update 2020-05-13

A small phase 2 — 50 participants, against a typical 110. The sponsor logged completion for April 2016. Primary outcome, as filed: Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Copenhagen
Sponsor type: Other
Enrollment: 50
Started: 2014-06
Primary completion: 2016-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.